Achillion Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes small molecule drug therapies for immune system disorders in the United States. Its lead drug candidate includes ACH-4471, an inhibitor of factor D that is Phase II clinical trials for patients with paroxysmal nocturnal hemoglobinuria and C3 glomerulopathy. The company is also developing ACH-5228, a factor D inhibitor that is in Phase I clinical trial; ACH-5548, a factor D inhibitor; and other factor D inhibitors. It has license agreements with GCA Therapeutics, Ltd and Ora, Inc., as well as a collaboration arrangement with Janssen Pharmaceuticals Inc. to develop and commercialize drug candidates for the treatment of chronic hepatitis C virus. The company was founded in 1998 and is headquartered in New Haven, Connecticut.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Phone203-624-7000
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$15 million
Profitability
Miscellaneous
Employees88
OptionableOptionable
Achillion Pharmaceuticals (NASDAQ:ACHN) Frequently Asked Questions
What is Achillion Pharmaceuticals' stock symbol?
Achillion Pharmaceuticals trades on the NASDAQ under the ticker symbol "ACHN."
How were Achillion Pharmaceuticals' earnings last quarter?
Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) released its quarterly earnings results on Wednesday, November, 7th. The biopharmaceutical company reported ($0.12) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($0.14) by $0.02. View Achillion Pharmaceuticals' Earnings History.
When is Achillion Pharmaceuticals' next earnings date?
What price target have analysts set for ACHN?
2 brokerages have issued twelve-month target prices for Achillion Pharmaceuticals' stock. Their forecasts range from $3.50 to $5.00. On average, they anticipate Achillion Pharmaceuticals' stock price to reach $4.25 in the next year. This suggests a possible upside of 95.0% from the stock's current price. View Analyst Price Targets for Achillion Pharmaceuticals.
What is the consensus analysts' recommendation for Achillion Pharmaceuticals?
2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Achillion Pharmaceuticals in the last year. There are currently 2 hold ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Achillion Pharmaceuticals.
Has Achillion Pharmaceuticals been receiving favorable news coverage?
Headlines about ACHN stock have been trending somewhat positive recently, according to InfoTrie. The research firm identifies negative and positive press coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Achillion Pharmaceuticals earned a news sentiment score of 1.4 on InfoTrie's scale. They also gave headlines about the biopharmaceutical company a news buzz of 5.0 out of 10, indicating that recent press coverage is somewhat likely to have an effect on the company's share price in the near term.
Are investors shorting Achillion Pharmaceuticals?
Achillion Pharmaceuticals saw a increase in short interest in the month of December. As of December 31st, there was short interest totalling 7,425,448 shares, an increase of 42.0% from the December 14th total of 5,230,507 shares. Based on an average trading volume of 5,878,756 shares, the days-to-cover ratio is currently 1.3 days. Currently, 5.5% of the company's shares are short sold. View Achillion Pharmaceuticals' Current Options Chain.
Who are some of Achillion Pharmaceuticals' key competitors?
Some companies that are related to Achillion Pharmaceuticals include Kiniksa Pharmaceuticals (KNSA), Uniqure (QURE), Spectrum Pharmaceuticals (SPPI), Esperion Therapeutics (ESPR), Rhythm Pharmaceuticals (RYTM), Amphastar Pharmaceuticals (AMPH), Deciphera Pharmaceuticals (DCPH), Puma Biotechnology (PBYI), Tricida (TCDA), Alder Biopharmaceuticals (ALDR), Retrophin (RTRX), Homology Medicines (FIXX), Apellis Pharmaceuticals (APLS), Inflarx (IFRX) and Athenex (ATNX).
Who are Achillion Pharmaceuticals' key executives?
Achillion Pharmaceuticals' management team includes the folowing people:
- Mr. Joseph Truitt, Pres, CEO & Director (Age 54)
- Ms. Martha E. Manning, Exec. VP, Gen. Counsel & Corp. Sec. (Age 64)
- Ms. Keri Lantz, Interim Principal Financial Officer, Principal Accounting Officer, Controller & VP of Fin. (Age 44)
- Mr. Paul Firuta, Exec. VP & COO (Age 53)
- Mr. Brian R. DiDonato, VP of Investor Relations & Corp. Communications (Age 52)
Who are Achillion Pharmaceuticals' major shareholders?
Which major investors are selling Achillion Pharmaceuticals stock?
Which major investors are buying Achillion Pharmaceuticals stock?
How do I buy shares of Achillion Pharmaceuticals?
Shares of ACHN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Achillion Pharmaceuticals' stock price today?
One share of ACHN stock can currently be purchased for approximately $2.18.
How big of a company is Achillion Pharmaceuticals?
Achillion Pharmaceuticals has a market capitalization of $302.19 million and generates $15 million in revenue each year. The biopharmaceutical company earns $-85,230,000.00 in net income (profit) each year or ($0.62) on an earnings per share basis. Achillion Pharmaceuticals employs 88 workers across the globe.
What is Achillion Pharmaceuticals' official website?
How can I contact Achillion Pharmaceuticals?
Achillion Pharmaceuticals' mailing address is 300 GEORGE STREET, NEW HAVEN CT, 06511. The biopharmaceutical company can be reached via phone at 203-624-7000.
MarketBeat Community Rating for Achillion Pharmaceuticals (NASDAQ ACHN)
MarketBeat's community ratings are surveys of what our community members think about Achillion Pharmaceuticals and other stocks. Vote "Outperform" if you believe ACHN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ACHN will underperform the S&P 500 over the long term. You may vote once every thirty days.
